Ravgen and Myriad in patent dispute over DNA testing tech
24-12-2020
Illumina to acquire Jeff Bezos-backed cancer testing company
23-09-2020
Michael Vi / Shutterstock.com
Pharmaceutical companies Illumina and Roche have been sued for allegedly infringing two patents covering the technology for non-invasive DNA testing by Maryland genetic testing company Ravgen.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Illumina, Roche, genetic testing, patent infringement, DNA, non-invasive, US District Court for the District of Delaware, diagnostic, innovation, Ravgen
